NasdaqGS:CLOVHealthcare
Clover Health (CLOV) Price-to-Sales Discount Challenges Skeptics as Profitability Forecast Strengthens
Clover Health Investments (CLOV) is currently unprofitable, but the company has managed to cut its losses by 25.5% per year over the past five years. Revenue is forecast to grow at 14.9% per year, outpacing the broader US market’s 10.4% growth rate. Meanwhile, earnings are expected to surge at an impressive 77.48% per year, with profitability anticipated within three years. While the share price has experienced volatility in recent months, investors are weighing the mix of swift growth and...